DUOPHARMA BIOTECH BERHAD (KLSE: 7148)

DUOPHARMA BIOTECH BERHAD

KLSE: 7148 (DPHARMA)

最近更新时间: 28分钟之前

1.31

-0.02 (-1.50%)

加入群组

前收盘价格	1.33
收盘价格	1.33
成交量	1,203,400
平均成交量 (3个月)	303,777
市值	1,260,144,000

市盈率 (P/E TTM)	18.71
预期市盈率 (P/E Forward)	13.30
价格/销量 (P/S)	1.53
股市价格/股市净资产 (P/B)	1.75

52周波幅	1.07 (-18%) — 1.45 (10%)
利润日期	21 May 2025 - 26 May 2025
股息率 (DY TTM)	2.29%

市场趋势

		短期	中期
行业	Drug Manufacturers - Specialty & Generic (MY)	混合的	混合的
	Drug Manufacturers - Specialty & Generic (全球的)	看跌	混合的
股票	DPHARMA	看涨	看涨

AIStockmoo 评分

1.4

分析师共识	5.0
内部交易活动	2.5
价格波动	-1.5
技术平均移动指标	-1.0
技术振荡指标	2.0
平均	1.40

相关股票

股票	市值	DY	P/E（TTM）	P/B
DPHARMA	1 B	2.29%	18.71	1.75
KOTRA	593 M	6.38%	14.81	2.44
YSPSAH	322 M	4.85%	11.95	0.760
RHONEMA	134 M	4.13%	15.13	0.800
PLABS	89 M	-	32.50	1.00

Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
部门	Healthcare
行业	Drug Manufacturers - Specialty & Generic
投资方式	Small Core
内部持股比例	2.64%
机构持股比例	71.74%

所有权

姓名	日期	持有股份
Billion Victory Sdn Bhd	31 Mar 2023	15,070,000 (1.57%)
Manulife Investment Shariah Progress Fund	31 Oct 2022	8,670,000 (0.90%)

52周波幅	1.07 (-18%) — 1.45 (10%)
目标价格波幅	1.50 (14%) — 1.70 (29%)
高	1.70 (TA, 29.77%)	购买
中	1.60 (22.14%)
低	1.50 (RHB, 14.50%)	购买
平均值	1.60 (22.14%)
总计	2 购买
平均价格@调整类型	1.29

公司	日期	目标价格	调整类型	价格@调整类型
RHB	16 May 2025	1.50 (14.50%)	购买	1.29
TA	16 May 2025	1.70 (29.77%)	购买	1.29
TA	29 Apr 2025	1.62 (23.66%)	购买	1.20

名称	平均购买 ($)	平均卖出 ($)	总净额	总净值 ($)
EMPLOYEES PROVIDENT FUND BOARD	1.23	-	300,000	367,454
累积净数量				300,000
累积净值 ($)				367,454
累积平均购买 ($)				1.23
累积平均卖出 ($)				-

名称	持有人	日期	类型	数量	价格	价值 ($)
EMPLOYEES PROVIDENT FUND BOARD	大股东	08 May 2025	获得 (+)	227,300	1.22	277,306
EMPLOYEES PROVIDENT FUND BOARD	大股东	07 May 2025	获得 (+)	72,700	1.24	90,148

日期	类型	细节
20 May 2025	TheEdge	MOH grants Duopharma six-month contract extension for insulin supply
15 May 2025	公告	Revised Administrative Guide
15 May 2025	公告	Duopharma Biotech Records 36.2% Revenue Growth and 67.8% Profit Improvement in Q1 FY2025
15 May 2025	公告	Quarterly rpt on consolidated results for the financial period ended 31/03/2025
15 May 2025	TheEdge	Duopharma posts record-high 1Q profit on strong sales, active ingredient price normalisation
14 May 2025	公告	Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
13 May 2025	公告	Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
13 May 2025	TheEdge	Duopharma set for strong 1Q growth backed by approved products purchase list contracts — CGS International
28 Apr 2025	TheEdge	Nestlé Malaysia, Bursa Malaysia, BAT Malaysia, F&N, Rohas Tecnic, MKH, Meta Bright, Duopharma Biotech, Pintaras Jaya, Johor Plantations
28 Apr 2025	TheEdge	Duopharma bags another supply contract from Pharmaniaga
28 Apr 2025	TheEdge	Dividend stocks regain appeal as global uncertainty looms
28 Apr 2025	公告	CONTRACTS FOR THE SUPPLY BY DUOPHARMA (M) SENDIRIAN BERHAD, DUOPHARMA MANUFACTURING (BANGI) SDN. BHD. AND DUOPHARMA HAPI SDN. BHD. (ALL WHOLLY-OWNED SUBSIDIARY COMPANIES OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN. BHD. OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
21 Apr 2025	公告	Annual Report & CG Report - 2024
21 Apr 2025	公告	Annual Audited Accounts - 31 Dec 2024
18 Apr 2025	公告	General Meetings: Notice of Meeting
17 Apr 2025	TheEdge	Cover Story: Healing old wounds and growing new income streams at Pharmaniaga
10 Apr 2025	TheEdge	Cover Story: Risk-off mode likely to continue in 2Q on continuous foreign fund outflows
09 Apr 2025	TheEdge	Duopharma Biotech bags supply contracts worth RM16.58m from govt in third round of award
09 Apr 2025	公告	CONTRACT FOR THE SUPPLY BY DUOPHARMA HAPI SDN. BHD. (A WHOLLY-OWNED SUBSIDIARY COMPANY OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN. BHD. OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
02 Apr 2025	TheEdge	Duopharma Biotech back on growth path as focus on revenue pays off
28 Mar 2025	公告	Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
26 Mar 2025	TheEdge	Special Report: Malaysia not ready for another pandemic, say health experts
14 Mar 2025	公告	Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
10 Mar 2025	公告	MATERIAL LITIGATION
27 Feb 2025	TheEdge	Cover Story: PNB tackling uphill battle of getting Malaysians to save
显示更多

股息率 (DY TTM)	2.29%
5年平均股息收益率	2.31%
股息支付比率	43.01%
预计下次股息支付	Sep 2025

除息日	公告日期	支付日期	详情
05 Mar 2025	19 Feb 2025	19 Mar 2025	0.02 现金
29 Aug 2024	15 Aug 2024	12 Sep 2024	0.01 现金
07 Mar 2024	22 Feb 2024	21 Mar 2024	0.018 现金
08 Sep 2023	24 Aug 2023	22 Sep 2023	0.005 现金
07 Apr 2023	27 Mar 2023	09 May 2023	0.018 现金
29 Aug 2022	16 Aug 2022	14 Sep 2022	0.005 现金
14 Apr 2022	24 Mar 2022	13 May 2022	0.018 现金
30 Aug 2021	17 Aug 2021	15 Sep 2021	0.005 现金
21 Apr 2021	08 Apr 2021	21 May 2021	0.06 现金
28 Aug 2020	13 Aug 2020	11 Sep 2020	0.005 现金
13 Jul 2020	30 Jun 2020	12 Aug 2020	0.05 现金
15 Oct 2019	02 Oct 2019	14 Nov 2019	0.01 现金
26 Jun 2019	13 Jun 2019	26 Jul 2019	0.04 现金
02 Nov 2018	22 Oct 2018	23 Nov 2018	0.015 现金
13 Jun 2018	31 May 2018	17 Jul 2018	0.06 现金
17 Oct 2017	25 Aug 2017	10 Nov 2017	0.025 现金
26 May 2017	24 Feb 2017	23 Jun 2017	0.04 现金
19 Oct 2016	22 Aug 2016	11 Nov 2016	0.025 现金
06 Jun 2016	23 Feb 2016	28 Jun 2016	0.055 现金
13 Oct 2015	25 Aug 2015	06 Nov 2015	0.04 现金
27 May 2015	24 Feb 2015	25 Jun 2015	0.145 现金
15 Oct 2014	26 Aug 2014	07 Nov 2014	0.04 现金
22 May 2014	26 Feb 2014	20 Jun 2014	0.135 现金
14 Oct 2013	28 Aug 2013	08 Nov 2013	0.04 现金
14 Jun 2013	22 Mar 2013	12 Jul 2013	0.105 现金
15 Oct 2012	16 Aug 2012	09 Nov 2012	0.035 现金
06 Jun 2012	16 Mar 2012	29 Jun 2012	0.145 现金
05 Oct 2011	18 Aug 2011	28 Oct 2011	0.035 现金
08 Jun 2011	21 Apr 2011	27 Jun 2011	0.11 现金
06 Oct 2010	02 Sep 2010	28 Oct 2010	0.045 现金
09 Jun 2010	21 Apr 2010	25 Jun 2010	0.12 现金
01 Oct 2009	26 Aug 2009	23 Oct 2009	0.06 现金
10 Jun 2009	15 Apr 2009	26 Jun 2009	0.07 现金
08 Oct 2008	26 Aug 2008	28 Oct 2008	Interim Dividend
03 Oct 2007	24 Aug 2007	18 Oct 2007	Interim Dividend
29 May 2007	25 Apr 2007	08 Jun 2007	Final Dividend
11 Sep 2006	23 Aug 2006	22 Sep 2006	Interim Dividend
18 May 2006	24 Apr 2006	08 Jun 2006	First and Final Dividend
26 Jul 2005	06 Jun 2005	18 Aug 2005	Final Dividend
21 Oct 2004	06 Oct 2004	08 Nov 2004	Interim Dividend
06 Jul 2004	01 Jun 2004	28 Jul 2004	Final Dividend
26 Sep 2003	09 Sep 2003	20 Oct 2003	Interim Dividend
23 Jun 2003	25 Apr 2003	08 Jul 2003	First and Final Dividend
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	0.020	1	1.52
2024	0.028	2	2.24
2023	0.023	2	1.83
2022	0.023	2	1.43
2021	0.065	2	3.87
2020	0.055	2	2.17
2019	0.050	2	4.70
2018	0.075	2	10.53
2017	0.065	2	7.99
2016	0.080	2	12.57
2015	0.185	2	21.97
2014	0.175	2	29.38
2013	0.145	2	23.59
2012	0.180	2	35.47
2011	0.145	2	30.13
2010	0.165	2	28.97
2009	0.130	2	23.22
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	7.70%
营业利益率 (TTM)	11.08%
稀释每股收益 (EPS TTM)	0.070
季度收入增长率 (YOY)	15.60%
季度盈利增长率 (YOY)	77.40%

总债务/股东权益 (D/E MRQ)	72.74%
流动比率 (MRQ)	4.08
营业现金流 (OCF TTM)	83.34 M
杠杆自由现金流 (LFCF TTM)	31.95 M

资产报酬率 (ROA TTM)	4.60%
股东权益报酬率 (ROE TTM)	8.97%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)